Champions Biotechnology Announces Master Service Agreement with Teva Pharmaceutical Industries, Ltd. for the Evaluation of a Novel Oncology Compound

Hackensack, NJ – December 7, 2010 – Champions Biotechnology, Inc. (OTC Bulletin Board : CSBR) an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.

Anti-angiogenic compounds are designed to work by blocking the tumor’s blood supply. There are multiple approved and experimental anti-angiogenic compounds for colorectal, breast, and lung cancer.  Teva is developing agents in this area to help treat various forms of cancer.  Under the terms of the agreement, Champions will use its Champions Tumorgraft™ platform to test the effectiveness of Teva’s compound in various cancer indications to assist in further clinical development.  “We are very excited to work with Teva on this program. The use of our highly-predictive Champions Tumorgraft™ platform will provide Teva with the data necessary for critical drug development decisions and help focus and accelerate the development program for this compound.” said Elizabeth Bruckheimer, Ph.D., Vice President of Scientific Operations, Champions Biotechnology, Inc.